Overview
There is a lack of knowledge on preference and concurrent or sequential use of available treatments for patients with germline BRCA1/2 pathogenic mutations (gBRCAm) and clinically high risk HER2-negative early breast cancer. This research aimed to describe real-world gBRCA testing rates and treatment patterns prior to and post the U.S. FDA approval of adjuvant olaparib for HER2 negative early breast cancer.
Using data on US patients over 18 years of age from the nationwide Flatiron Health EHR-derived database, this research found 55% of patients with HR+/HER2- early breast cancer and 27% with triple negative breast cancer did not receive a gBRAC test and low utilization of adjuvant olaparib, particularly among patients with HR+/HER2- early breast cancer.
Why this matters
Using real-world data, this research provides evidence that may improve understanding of treatment and testing patterns for patients with early breast cancer. The results highlight a gap in genetic testing and utilization of olaparib to treat eligible patients with eBC.